Best Tech News Site

If you’re adventurous with your food, or just like to keep up with the fast-moving food tech industry, here’s a roundup of this week’s stories and some notable news we weren’t able to cover. Supply Change Capital The venture capital fund madness we’ve seen all year has made its way to the food sector. This week, I wrote about Supply Change Capital , which closed on $40 million in capital commitments for its first fund, targeting investments in the global food industry. The female and Latina-owned firm is spearheaded by co-founders and managing partners Noramay Cadena and Shayna Harris, who met 14 years ago in business school. The firm has already made 15 investments, including in allergen-free snack food company Partake Foods , ingredients startup Michroma and alternative seafood maker Aqua Cultured Foods . Supply Change joins firms like Joyful Ventures, which debuted in June with $23 million , focused on investment in sustainable protein startups. Joyful was co-founded by Jenni...

If you’re adventurous with your food, or just like to keep up with the fast-moving food tech industry, here’s a roundup of this week’s stories and some notable news we weren’t able to cover. Supply Change Capital The venture capital fund madness we’ve seen all year has made its way to the food sector. This week, I wrote about Supply Change Capital , which closed on $40 million in capital commitments for its first fund, targeting investments in the global food industry. The female and Latina-owned firm is spearheaded by co-founders and managing partners Noramay Cadena and Shayna Harris, who met 14 years ago in business school. The firm has already made 15 investments, including in allergen-free snack food company Partake Foods , ingredients startup Michroma and alternative seafood maker Aqua Cultured Foods . Supply Change joins firms like Joyful Ventures, which debuted in June with $23 million , focused on investment in sustainable protein startups. Joyful was co-founded by Jenni...

W elcome to the TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here . Today, a look at Israel from three different angles: drug discovery, AI-enabled cybersecurity threats, and investor reactions to the political crisis. — Anna From spatial biology to proteomics Chipmaker Nvidia invested $50 million into biotech startup Recursion, which now plans to “accelerate [the] development of its AI foundation models for biology and chemistry,” according to a press release. Recursion CTO Ben Mabey said the company aims to build “a definitive foundation model for the drug discovery space.” That’s no easy feat; its CEO Chris Gibson referred to drug discovery as “one of the world’s most difficult challenges.” However, both Recursion and Nvidia hope AI can help solve this challenge. “Generative AI is a revolutionary tool to discover new medicines and treatment...

W elcome to the TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here . Today, a look at Israel from three different angles: drug discovery, AI-enabled cybersecurity threats, and investor reactions to the political crisis. — Anna From spatial biology to proteomics Chipmaker Nvidia invested $50 million into biotech startup Recursion, which now plans to “accelerate [the] development of its AI foundation models for biology and chemistry,” according to a press release. Recursion CTO Ben Mabey said the company aims to build “a definitive foundation model for the drug discovery space.” That’s no easy feat; its CEO Chris Gibson referred to drug discovery as “one of the world’s most difficult challenges.” However, both Recursion and Nvidia hope AI can help solve this challenge. “Generative AI is a revolutionary tool to discover new medicines and treatment...

Building a startup is hard enough but growing one in a category marred with Theranos-sized stigma is a new level of challenge. Vital Bio seems up for the test. The Toronto-based startup is building a machine, VitalOne, that can perform more than 50 blood tests — covering nearly all of those considered routine — and get patient results back in 20 minutes, not multiple days. Co-founder and CEO Vasu Nadella said that he got interested in the space because he and his co-founders have watched family members deal with chronic illness and know that being able to get quick diagnostic results is crucial for treatment. Plus, Nadella wanted to know why companies couldn’t seem to get the solution to this problem right. While Theranos failed for a variety of reasons, the other companies trying to build these quicker blood diagnostic tools had yet to ship products. He thought maybe he could crack the code. The startup launched in 2019 and built quietly until it debuted its device at the American ...

Building a startup is hard enough but growing one in a category marred with Theranos-sized stigma is a new level of challenge. Vital Bio seems up for the test. The Toronto-based startup is building a machine, VitalOne, that can perform more than 50 blood tests — covering nearly all of those considered routine — and get patient results back in 20 minutes, not multiple days. Co-founder and CEO Vasu Nadella said that he got interested in the space because he and his co-founders have watched family members deal with chronic illness and know that being able to get quick diagnostic results is crucial for treatment. Plus, Nadella wanted to know why companies couldn’t seem to get the solution to this problem right. While Theranos failed for a variety of reasons, the other companies trying to build these quicker blood diagnostic tools had yet to ship products. He thought maybe he could crack the code. The startup launched in 2019 and built quietly until it debuted its device at the American ...

Trey Herr Contributor Trey Herr is the director of the Atlantic Council’s Cyber Statecraft Initiative. Maia Hamin Contributor Maia Hamin is an associate director with the Cyber Statecraft Initiative. Will Loomis Contributor Share on Twitter Will Loomis is an associate director with the Cyber Statecraft Initiative. Stewart Scott Contributor Stewart Scott is an associate director with the Cyber Statecraft Initiative. The Biden administration’s 2023 National Cybersecurity Strategy identified structural shortcomings in the state of cybersecurity, calling out the failure of market forces to adequately distribute responsibility for the security of data and digital systems. Most prominently, the strategy seeks to “rebalance responsibility [for security] to those best positioned.” Shortly after the strategy’s launch in March of this year, the Cybersecurity and Infrastructure Security Agency (CISA) kicked off an effort to “shift the balance of cybersecuri...